The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
Open accessAbstract
β-Cell function improves in patients with type 2 diabetes in response to an oral glucose stimulus after Roux-en-Y gastric bypass (RYGB) surgery. This has been linked to the exaggerated secretion of glucagon-like peptide 1 (GLP-1), but causality has not been established. The aim of this study was to investigate the role of GLP-1 in improving β-cell function and glucose tolerance and regulating glucagon release after RYGB using exendin(9-39) (Ex-9), a GLP-1 receptor (GLP-1R)–specific antagonist. Nine patients with type 2 diabetes were examined before and 1 week and 3 months after surgery. Each visit consisted of two experimental days, allowing a meal test with randomized infusion of saline or Ex-9. After RYGB, glucose tolerance improved, β-cell glucose sensitivity (β-GS) doubled, the GLP-1 response greatly increased, and glucagon secretion was augmented. GLP-1R blockade did not affect β-cell function or meal-induced glucagon release before the operation but did impair glucose tolerance. After RYGB, β-GS decreased to preoperative levels, glucagon secretion increased, and glucose tolerance was impaired by Ex-9 infusion. Thus, the exaggerated effect of GLP-1 after RYGB is of major importance for the improvement in β-cell function, control of glucagon release, and glucose tolerance in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationPories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293
Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes
Mingrone, G., Panunzi, S., De Gaetano, A., Guidone, C., Iaconelli, A., Leccesi, L., Nanni, G., Pomp, A., Castagneto, M., Ghirlanda, G., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200111 · Cited by 1,791
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus
Schauer, P. R., Burguera, B., Ikramuddin, S., Cottam, D., Gourash, W., Hamad, G., Eid, G. M., Mattar, S., Ramanathan, R., Barinas-Mitchel, E., et al. (2003) · Annals of Surgery · doi:10.1097/01.sla.0000089851.41115.1b · Cited by 1,183 · cited 2×
“Preoperatively, one patient was treated with diet alone and eight were treated with metformin either as monotherapy (n = 4) or in combination with glimepiride (1), vildagliptin (1), liraglutide (1), or liraglutide and insulin glargine (1).”
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · cited 3×
“This was accomplished by pharmacologically blocking the GLP-1 receptor (GLP-1R) during a liquid meal tolerance test before and after surgery using exendin(9-39) (Ex-9; Bachem AG, Bubendorf, Switzerland), a specific GLP-1R antagonist (16).”
BackgroundMethodThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Verdich, C., Toubro, S., Buemann, B., Lysgård Madsen, J., Juul Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801655 · Cited by 434
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Self-citationEdwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 3×
“This was accomplished by pharmacologically blocking the GLP-1 receptor (GLP-1R) during a liquid meal tolerance test before and after surgery using exendin(9-39) (Ex-9; Bachem AG, Bubendorf, Switzerland), a specific GLP-1R antagonist (16).”
MethodJacobsen, S. H., Olesen, S. C., Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Kielgast, U., Worm, D., Almdal, T., Naver, L. S., Hvolris, L. E., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0621-4 · Cited by 342
Self-citationSalehi, M., Prigeon, R. L., & D’Alessio, D. A. (2011) · Diabetes · doi:10.2337/db11-0203 · Cited by 323
Falkén, Y., Hellström, P. M., Holst, J. J., & Näslund, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2876 · Cited by 315
Self-citationJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Insulin transport across capillaries is rate limiting for insulin action in dogs.
Yang, Y. J., Hope, I. D., Ader, M., & Bergman, R. N. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114339 · Cited by 303
Role of Glucose Effectiveness in the Determination of Glucose Tolerance
Best, J. D., Kahn, S. E., Ader, M., Watanabe, R. M., Ni, T. C., & Bergman, R. N. (1996) · Diabetes Care · doi:10.2337/diacare.19.9.1018 · Cited by 290
Kashyap, S. R., Daud, S., Kelly, K. R., Gastaldelli, A., Win, H., Brethauer, S., Kirwan, J. P., & Schauer, P. R. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.254 · Cited by 274
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Isbell, J. M., Tamboli, R. A., Hansen, E. N., Saliba, J., Dunn, J. P., Phillips, S. E., Marks-Shulman, P. A., & Abumrad, N. N. (2010) · Diabetes Care · doi:10.2337/dc09-2107 · Cited by 248
HENRY, R. R., SCHEAFFER, L., & OLEFSKY, J. M. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-61-5-917 · Cited by 245
Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass
Dirksen, C., Jørgensen, N. B., Bojsen-Møller, K. N., Jacobsen, S. H., Hansen, D. L., Worm, D., Holst, J. J., & Madsbad, S. (2012) · Diabetologia · doi:10.1007/s00125-012-2556-7 · Cited by 239
Self-citationCamastra, S., Gastaldelli, A., Mari, A., Bonuccelli, S., Scartabelli, G., Frascerra, S., Baldi, S., Nannipieri, M., Rebelos, E., Anselmino, M., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2193-6 · Cited by 196
Dirksen, C., Damgaard, M., Bojsen‐Møller, K. N., Jørgensen, N. B., Kielgast, U., Jacobsen, S. H., Naver, L. S., Worm, D., Holst, J. J., Madsbad, S., et al. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12087 · Cited by 184
Nannipieri, M., Mari, A., Anselmino, M., Baldi, S., Barsotti, E., Guarino, D., Camastra, S., Bellini, R., Berta, R. D., & Ferrannini, E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0446 · Cited by 178
ISEC: a program to calculate insulin secretion
Hovorka, R., Soons, P. A., & Young, M. A. (1996) · Computer Methods and Programs in Biomedicine · doi:10.1016/0169-2607(96)01755-5 · Cited by 177
Ilial Transposition and Enteroglucagon/GLP-1 in Obesity (and Diabetic?) Surgery
Mason, E. E. (1999) · Obesity Surgery · doi:10.1381/096089299765553070 · Cited by 153
Krarup, T., Madsbad, S., Moody, A. J., Regeur, L., FABER, O. K., Holst, J. J., & Sestoft, L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1306 · Cited by 150
Self-citationDeacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 147
Self-citationGLP-1 and Changes in Glucose Tolerance following Gastric Bypass Surgery in Morbidly Obese Subjects
Morínigo, R., Lacy, A. M., Casamitjana, R., Delgado, S., Gomis, R., & Vidal, J. (2006) · Obesity Surgery · doi:10.1381/096089206779319338 · Cited by 145
Umeda, L. M., Silva, E. A., Carneiro, G., Arasaki, C. H., Geloneze, B., & Zanella, M. T. (2011) · Obesity Surgery · doi:10.1007/s11695-011-0412-3 · Cited by 137
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Self-citationNäslund, E. B., Bäckman, L., Holst, J. J., Theodorsson, E., & Hellström, P. M. (1998) · Obesity Surgery · doi:10.1381/096089298765554449 · Cited by 133
Self-citationEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes
Taylor, R. (2012) · Diabetic Medicine · doi:10.1111/dme.12039 · Cited by 121
Dunn, J. P., Abumrad, N. N., Breitman, I., Marks–Shulman, P. A., Flynn, C. R., Jabbour, K., Feurer, I. D., & Tamboli, R. A. (2011) · Diabetes Care · doi:10.2337/dc11-1383 · Cited by 118
Roux-en-Y Gastric Bypass Corrects Hyperinsulinemia Implications for the Remission of Type 2 Diabetes
Reed, M. A., Pories, W. J., Chapman, W. H. H., Pender, J. R., Bowden, R., Barakat, H. A., Gavin, T. P., Green, T., Tapscott, E., Zheng, D., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0165 · Cited by 114
Serre‐Beinier, V., Dolci, W., Schaerer, E., Scrocchi, L. A., Drucker, D. J., Efrat, S., & Thorens, B. (1998) · Endocrinology · doi:10.1210/endo.139.11.6295 · Cited by 113
Malandrucco, I., Pasqualetti, P., Giordani, I., Manfellotto, D., Marco, F. D., Alegiani, F., Sidoti, A. M., Picconi, F., Flaviani, A. D., Frajese, G., et al. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.023697 · Cited by 113
Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 109
Self-citationEffect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus
Schauer, P., Burguera, B., Ikramuddin, S., Cottam, D., Gourash, W., Hamad, G., Eid, G., Mattar, S., Ramanathan, R., Barinas‐Mitchel, E., et al. (2004) · Nutrition in Clinical Practice · doi:10.1177/011542650401900160 · Cited by 95
Nicolaus, M., Brödl, J., Linke, R., Woerle, H., Göke, B., & Schirra, J. R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0841 · Cited by 75
Assessment of hepatic insulin action in obese type 2 diabetic patients
Staehr, P., Hother-Nielsen, O., Levin, K., Holst, J. J., & Beck-Nielsen, H. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1363 · Cited by 74
Self-citationWoerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
Raufman, J., Singh, L., & Eng, J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49932-2 · Cited by 65
Svendsen, P. F., Jensen, F. K., Holst, J. J., Haugaard, S. B., Nilas, L., & Madsbad, S. (2012) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.691542 · Cited by 57
Self-citationLin, E., Liang, Z., Frediani, J. K., Davis, S. S., Sweeney, J. F., Ziegler, T. R., Phillips, L. S., & Gletsu-Miller, N. A. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00405.2010 · Cited by 57
Ader, M., Poulin, R. A., Yang, Y. J., & Bergman, R. N. (1992) · Diabetes · doi:10.2337/diab.41.2.241 · Cited by 20
Meier, J. J., Pennartz, C., Schenker, N., Menge, B., Schmidt, W. E., Heise, T., Kapitza, C., & Veldhuis, J. D. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12022 · Cited by 18
Cited by
Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium
Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Metadata
- Authors
- Jørgensen, N. B., Dirksen, C., Bojsen-Møller, K. N., Jacobsen, S. H., Worm, D., Hansen, D. L., Kristiansen, V. B., Naver, L., Madsbad, S., & Holst, J. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-08-15
- Volume
- 62
- Issue
- 9
- Pages
- 3044-3052
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2095971031
- Cited by
- 288
- References
- 53
- FWCI
- 29.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.